Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms



Rating:

Share or cite this content

Citations should be made in the following way:
N. Peled (Tel Aviv, Israel). The clinical benefit of personalised medicine in lung cancer. International Congress 2014 – Understanding the benefit of current personalised medicine platforms

Member's Comments

No comment yet.

Related content which might interest you: The future of personalised medicine in COPD Source: International Congress 2016 – Endotyping: the means to personalised medicine in lung disease Year: 2016 Pathology meets clinic: translating lung cancer pathology into personalised care Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 The effectiveness of a multidisciplinary approach in the management of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 495s Year: 2005 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 Practical tools for implementing early palliative care in advanced lung cancer Source: Eur Respir J 2016; 47: 1010-1012 Year: 2016 Towards personalized lung cancer CT screening in Europe Source: Virtual Congress 2020 – Screening and imaging in lung cancer Year: 2020 PG1 Re-defining the role of chest physicians in lung cancer:ÿnew opportunities in diagnostics and therapy Source: Milan 2017 - Educational material Year: 2017 The impact of personalised therapies on respiratory medicine Source: Eur Respir Rev 2013; 22: 72-74 Year: 2013 End-of-life antimicrobial usage in lung cancer: current perpectives and clinical practice Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 Defining a standard set of patient-centred outcomes for lung cancer Source: Eur Respir J 2016; 48: 852-860 Year: 2016 Milestones in the management of lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Precision medicine for lung cancer: new targeted treatments  Source: International Congress 2017 – Precision medicine approaches in lung cancer Year: 2017 Delays in lung cancer management Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 New and anticipated therapeutic developments in management of non-small-cell lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 Slow-growing lung cancer as an emerging entity: from screening to clinical management Source: Eur Respir J 2013; 42: 1706-1722 Year: 2013 Multimodal therapeutic approach for locally advanced NSCLC in everyday practice Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Management of lung cancer screening and incidental findings as well as their integration in existing lung cancer care Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 CC3 Lung cancer: personalised treatment and palliative care  Source: Paris 2018 - Educational material Year: 2018 Modern staging in lung cancer: from the current multidisciplinary process to novel approaches Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019